BioSpace38m
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
AstraZeneca price target raised to 13,100 GBp from 12,600 GBp at Guggenheim
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
AstraZeneca rises Thursday, outperforms market
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
Harnessing AI and data science to discover life-changing medicines at AstraZeneca
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca’s Calquence combination approved in U.S.
Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...
PMLiVE4h
AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma
AstraZeneca’s (AZ) Calquence (acalabrutinib) has been approved by the US Food and Drug Administration (FDA) as part of a ...
News Medical on MSN1d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.Cho0xxI9.js ...
AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab
AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...